Hematopoietic stem cells for treatment of early-onset type I diabetes mellitus
This study aims to evaluate the safety and efficacy of inactivation of the immune system, by means of chemotherapy and immunotherapy and infusion of autologous bone marrow-derived hematopoietic stem cells in early onset type 1 diabetes mellitus. Many of the treated patients remained non-insulin dependent for up to 2 years and there was an increase of c-peptide production. However, diabetic ketoacidosis reduced treatment effect and patients experiencing this may be less suitable for the proposed treatment.
Read More
Product Information for
Hematopoietic stem cells for treatment of early-onset type I diabetes mellitus